CJ Bioscience Statistics

Total Valuation

CJ Bioscience has a market cap or net worth of KRW 121.51 billion. The enterprise value is 73.92 billion.

Market Cap	121.51B
Enterprise Value	73.92B

Important Dates

The last earnings date was Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 34.23% in one year.

Current Share Class	13.07M
Shares Outstanding	13.07M
Shares Change (YoY)	+34.23%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	3.54%
Owned by Institutions (%)	0.11%
Float	4.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	35.99
PB Ratio	2.05
P/TBV Ratio	2.56
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.61
EV / Sales	21.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.89

Financial Position

The company has a current ratio of 3.89, with a Debt / Equity ratio of 0.14.

Current Ratio	3.89
Quick Ratio	3.84
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	-0.32
Interest Coverage	-53.28

Financial Efficiency

Return on equity (ROE) is -52.81% and return on invested capital (ROIC) is -29.68%.

Return on Equity (ROE)	-52.81%
Return on Assets (ROA)	-25.61%
Return on Invested Capital (ROIC)	-29.68%
Return on Capital Employed (ROCE)	-47.81%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.05
Inventory Turnover	14.15

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.45% in the last 52 weeks. The beta is 0.60, so CJ Bioscience's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	-15.45%
50-Day Moving Average	9,355.60
200-Day Moving Average	9,917.05
Relative Strength Index (RSI)	53.17
Average Volume (20 Days)	20,097

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CJ Bioscience had revenue of KRW 3.38 billion and -28.31 billion in losses. Loss per share was -2,313.56.

Revenue	3.38B
Gross Profit	427.40M
Operating Income	-29.44B
Pretax Income	-28.31B
Net Income	-28.31B
EBITDA	-25.36B
EBIT	-29.44B
Loss Per Share	-2,313.56

Full Income Statement

Balance Sheet

The company has 55.82 billion in cash and 8.23 billion in debt, giving a net cash position of 47.59 billion or 3,642.54 per share.

Cash & Cash Equivalents	55.82B
Total Debt	8.23B
Net Cash	47.59B
Net Cash Per Share	3,642.54
Equity (Book Value)	59.16B
Book Value Per Share	4,526.81
Working Capital	42.73B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -25.45 billion and capital expenditures -156.93 million, giving a free cash flow of -25.61 billion.

Operating Cash Flow	-25.45B
Capital Expenditures	-156.93M
Free Cash Flow	-25.61B
FCF Per Share	-1,960.22

Full Cash Flow Statement

Margins

Gross Margin	12.66%
Operating Margin	-872.04%
Pretax Margin	-838.73%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CJ Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-34.23%
Shareholder Yield	-34.23%
Earnings Yield	-23.30%
FCF Yield	-21.08%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CJ Bioscience has an Altman Z-Score of 1.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.26
Piotroski F-Score	3